These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24206882)

  • 21. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    JACC Cardiovasc Interv; 2011 Mar; 4(3):310-6. PubMed ID: 21435609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Heart Vessels; 2019 Feb; 34(2):237-250. PubMed ID: 30167772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
    Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel versus sirolimus eluting stents in diabetic patients: does stent type and/or stent diameter matter?: long-term clinical outcome of 2,429-patient multicenter registry.
    Tarantini G; Facchin M; Capodanno D; Musumeci G; Saia F; Menozzi A; Meliga E; Mancone M; Lettieri C; Tamburino C
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):80-9. PubMed ID: 22511311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial.
    Hong SJ; Kim MH; Cha KS; Park HS; Chae SC; Hur SH; Gwon HC; Bae JH; Lim DS
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):924-33. PubMed ID: 20815045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry.
    Tamburino C; Di Salvo ME; Capodanno D; Capranzano P; Parisi R; Mirabella F; Scardaci F; Ussia G; Galassi AR; Fiscella D; Mehran R; Dangas G
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):243-8. PubMed ID: 19156896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
    Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
    Rodriguez AE; Vigo CF; Delacasa A; Mieres J; Fernandez-Pereira C; Bernardi V; Bettinoti M; Rodriguez-Granillo AM; Rodriguez-Granillo G; Santaera O; Curotto V; Rubilar B; Tronge J; Palacios IF; Antoniucci D;
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):335-42. PubMed ID: 20824769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial.
    Jiménez-Quevedo P; Hernando L; Gómez-Hospital JA; Iñiguez A; SanRoman A; Alfonso F; Hernández-Antolín R; Angiolillo DJ; Bañuelos C; Escaned J; Gonzalo N; Fernández C; Macaya C; Sabaté M;
    EuroIntervention; 2013 Jul; 9(3):328-35. PubMed ID: 23518240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study evaluating efficacy of polymer free Pronova XR stent in treatment of denovo coronary artery stenosis.
    Deshpande NV; Admane P; Deshpande M; Mardikar HM
    Indian Heart J; 2014; 66(1):11-5. PubMed ID: 24581090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative assessment of mammalian target of rapamycin inhibitor-eluting stents in the treatment of coronary artery bifurcation lesions: the CASTOR-Bifurcation registry.
    Sgueglia GA; Burzotta F; Trani C; Todaro D; Talarico GP; Niccoli G; Porto I; Leone AM; Coluccia V; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Catheter Cardiovasc Interv; 2011 Mar; 77(4):503-9. PubMed ID: 20602477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects.
    Nakamura M; Otsuka Y; Ueda Y; Mitsudo K
    Cardiovasc Interv Ther; 2012 Jan; 27(1):24-30. PubMed ID: 24122637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.